---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-030373"
form_type: "8-K"
ticker: null
cik: "0001576263"
company_name: "Mirati Therapeutics, Inc."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T04:48:43.865094+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mirati Therapeutics CFO Stelzer to depart Sept 8; Aaron Ondrey named interim CFO

## Summary
- CFO Laurie Stelzer resigns effective Sept 8, 2023 to pursue opportunity at another biotech; will consult through Oct 2023.
- Aaron Ondrey (SVP FP&A since July 2022) appointed interim CFO; base salary increased to $450k.
- Ondrey receives retention award: $300k cash plus $300k in RSUs vesting 90 days after permanent CFO hired.
- Mirati recently completed an upsized public offering, extending cash runway through upcoming milestones.

## SEC filing metadata
- accession: 0001628280-23-030373
- form_type: 8-K
- cik: 0001576263
- company_name: Mirati Therapeutics, Inc.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/0001628280-23-030373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/mrtx-20230817.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-030373
- JSON: https://secwatch.observer/filing/0001628280-23-030373.json
- Plain text: https://secwatch.observer/filing/0001628280-23-030373.txt

## Key facts
- Executive change
  Laurie Stelzer resigned as Chief Financial Officer at Mirati Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On August 17, 2023, Laurie Stelzer notified Mirati Therapeutics, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Financial Officer and principal financial and accounting officer, effective as of September 8, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/0001628280-23-030373-index.htm
- Executive change
  Aaron Ondrey was appointed as Interim Chief Financial Officer at Mirati Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On August 21, 2023, the Board of Directors of the Company (the “Board”) appointed Aaron Ondrey, the Company’s Senior Vice President, Financial Planning and Analysis, as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of the Separation Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576263/000162828023030373/0001628280-23-030373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.